home / stock / otlkw / otlkw news

OTLKW News and Press, Outlook Therapeutics Inc. Series A Warrant From 02/02/21

Stock Information
Company Name: Outlook Therapeutics Inc. Series A Warrant
Stock Symbol: OTLKW
Market: NASDAQ
Website: outlooktherapeutics.com
Menu
OTLKW OTLKW Quote OTLKW Short OTLKW News OTLKW Articles OTLKW Message Board
Get OTLKW Alerts

News, Short Squeeze, Breakout and More Instantly...
OTLKW - Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal

MONMOUTH JUNCTION, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizum...
OTLKW - Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million

MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizum...

OTLKW - Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock

MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizum...

OTLKW - Leading Ophthalmology Organization Launches Podcast Video with Firas Rahhal, MD, to Explore the Genesis and Promise of Outlook Therapeutics' ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

Leading retina clinician Dr. Rahhal discusses the market need for an FDA-approved ophthalmic bevacizumab for treating wet AMD and other retinal diseases Terry Dagnon, COO, and Jeff Evanson, CCO, of Outlook Therapeutics share the clinical rationale and regulatory framework for de...
OTLKW - Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

MONMOUTH JUNCTION, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinalȂ...

OTLKW - Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update

All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in secon...

OTLKW - Outlook Therapeutics Announces Creation of Global Retina Advisory Council

Advisory Co uncil to collaborate on ou t reach to retinal clinicians to support development and commercialization of ONS-5010, an investigational ophthalmic formulation of bevac i zumab MONMOUTH JUNCTION, N.J., Nov. 19, 2020 (GLOBE NEWSW...
OTLKW - Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA(TM)

Dr. Rahhal , a leading retinal clinician, offer ed insight on wet AMD treatment and the p otential of ONS-5010/ LYTENA VA ™ (bevacizumab-vikg) , if approved, to improve available treatment options ...

OTLKW - Outlook Therapeutics Secures $10 Million in Additional Working Capital

MONMOUTH JUNCTION, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinalȂ...

OTLKW - Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

Full enrollment of 195 subjects in NORSE THREE achieved in less than one month, significantly ahead of schedule All planned clinical trials for ONS-5010/LYTENAVA ™ BLA for wet AMD now fully enrolled or comple...
Previous 10 Next 10